Increasing drug candidate predictability earlier in the discovery pipeline using non-cell-based assays can improve candidate throughput during the ADME stage. Non-cell-based permeability assays are predictive models for oral absorption of development candidates.MultiScreen Permeability, MultiScreen-IP, and MultiScreen Acceptor plates support artificial membrane strategies for predicting passive transport.Membranes have uniform pore structure and density for reliable transport: - Individual wells minimize candidate cross-talk - Compatibility with automated liquid handling systems increases throughput Permeability Assay: - The MultiScreen Permeability plate has a polycarbonate membrane, which supports a hexane/hexadecane artificial layer for permeability assays.1PAMPA Assay: - The MultiScreen-IP plate has a hydrophobic PVDF membrane, which supports a lipid bilayer for PAMPA asays.2,3MultiScreen Acceptor Plate: - The MultiScreen Acceptor plate can be used with either plate to capture passively transported compounds. Constructed of 100% PTFE, the plate can improve LC/MS results depending on the charge of the small molecules being evaluated.
Application: Research CategoryAssaysProtein
Legal Information: MULTISCREEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes: Automation Compatible: No